Pearl -a member of the AstraZeneca Group and AstraZeneca, Morristown, NJ, United States Background and Aims: COPD is a major public health concern in China. We assessed the efficacy and safety of GFF MDI vs placebo MDI and monocomponents in patients with moderate-to-very severe COPD in the China subpopulation of the PINNACLE-4 study (NCT02343458).
Methods: In this 24-week, randomized, double-blind, parallel-group, Phase III study, patients received twice-daily GFF MDI 14.4/10 μg, formoterol fumarate dihydrate (FF) MDI 10 μg, glycopyrronium (GP) MDI 14.4 μg, or placebo MDI. Efficacy endpoints are shown in the Table. Results: The intent-to-treat population in China included 466 patients (96% male; 33% current smokers; mean post-bronchodilator FEV 1 , 54% predicted). GFF MDI improved the change from baseline in morning predose trough FEV 1 at Week 24 (primary endpoint; China approach) vs placebo MDI (least squares mean difference 173 mL), GP MDI (98 mL), and FF MDI (104 mL, all P ≤ 0.0001). Improvements in secondary lung function and symptomatic endpoints were also observed for GFF MDI vs comparators (Table) . Adverse event frequency was similar across treatments.
Conclusion: GFF MDI improved lung function and symptoms in the PINNACLE-4 China subpopulation. Efficacy and safety results were consistent with the total patient population and support the use of GFF MDI in Chinese patients with moderate-to-very severe COPD. for patients with COPD suppresses eosinophilic inflammation of the airway, and may possibly reduce acute exacerbation. On the other hand, however, ICS may raise the risk of pneumonia. We classified patients with COPD by blood eosinophil counts and retrospectively evaluated the benefit and risk of ICS treatment.
Methods: A total of 244 patients with COPD enrolled between 2014 and 2017 were assigned to groups with blood eosinophil counts of ≥300/ μL and < 300/μL, respectively. Moreover, we divided these groups into subgroups with and without ICS treatment, and statistically compared the incident rate of acute exacerbation and merger of pneumonia in each group.
Results: Of the 244 patients with COPD, 97 (39.8%; 33 with and 64 without ICS) and 147 (46 with and 101 without ICS) had blood eosinophil counts of ≥300/μL (group 1) and < 300/μL (group 2), respectively. In group 1, a significantly lower incidence rate of acute exacerbation was noted in the ICS than in the non-ICS groups (P = 0.023), while there was no difference in group 2. Regarding merger of pneumonia on acute exacerbation, there was no significant difference between the ICS groups in group 1, while in group 2 the ICS group had a higher incidence (P = 0.009).
Conclusion:
We concluded that the blood eosinophil count was a useful marker for suppression of acute exacerbation by ICS treatment. Also, ICS treatment did not increase the risk of pneumonia in patients with blood eosinophil counts of ≥300/μL, but the risk was increased in patients with < 300/μL. To identify the presence of eosinophilic inflammation by checking blood eosinophil counts may lead to obtain a long-term prognosis in patients with COPD.
Respirology ( 
